Search

GENEVA—Reviews of CD8-positive T-cell infiltration as an independent prognostic biomarker in resected non-small cell lung cancer, and the potential of checkpoint inhibitor therapy for mesothelioma aft

GENEVA—First or second-line chemotherapy with cisplatin-pemetrexed or gemcitabine does not preclude the use of checkpoint inhibitor therapy for mesothelioma later on—according to research presented at

GENEVA—The use of combinations including checkpoint inhibition with other immunotherapies, other targeted therapies and chemotherapy was discussed at the European Lung Cancer Conference by Martin Reck

GENEVA—The recent success of treatment with immune checkpoint inhibitors suggests that immunotherapy could presently move center stage to play a leading role in fighting non-small cell lung cancer—the

GENEVA—Evidence presented at the 2015 European Lung Cancer conference from the large SQUIRE multicenter open label study points to the fact that older patients with squamous non small cell lung cancer

GENEVA—Toxicities from targeted agents used in lung cancer differ from those encountered with other drugs but can be managed successfully if recognized early and treated. At the European Lung Cancer C

GENEVA—The potential for using vaccines as important weapons against non small cell lung cancer has not yet been realized according to Johan Vansteenkiste MD PhD, an oncologist and professor of medici

VIENNA—Three key targetable pathways for breast cancer treatment were assessed at the St Gallen Breast Cancer Conference by Clifford Hudis, MD, Chief of the Breast Medicine Service at Memorial Sloan-K

VIENNA—Obesity and insulin resistance were named as important targets for primary prevention of breast cancer by Pamela J. Goodwin, MD, MSc, FRCPC, Professor of Medicine and Director of the Marvelle K

VIENNA—The bone microenvironment was regarded as a worthy target for breast cancer treatment in comments at the St Gallen Breast Cancer Conference from Michael Gnant MD, a Professor and Director of th

VIENNA—At the St Gallen Breast Cancer Conference BCL-2 was named as a therapeutic target for patients with hormone-receptor positive breast cancer by Geoffrey J Lindeman BSc(Med) PhD, from the Univers

VIENNA—Because harnessing the immune system is now proven as a way of managing breast cancer, clinicians should consider the role of tumor infiltrating lymphocytes, according to Giuseppe Curigliano MD